INTRODUCTION
The American Cancer Society estimates that by the year 2030, 70% of all cancers in United States will be diagnosed in senior adults. 1 The multiple layers of specialists (ie, oncologists, radiation oncologists, surgeons, geriatricians), primary care, and allied health professionals in the continuum of care makes this population a challenge to manage. Older adults with cancer are particularly prone to medication errors attributed to medication changes, complex regimens, and incomplete information handoff between providers. 2,3 Polypharmacy (PP) and poten-tially inappropriate medication (PIM) use warrant substantial interest and concern on behalf of medical oncologists and oncology health providers because of the perils associated with their use in this vulnerable population; vulnerabilities include increased risk of falls and/or fractures, cognitive impairment, and delirium, all of which can lead to compromised cancer management plans (eg, treatment delays and/or premature treatment discontinuation). Cancer-related therapy adds to the prevalence of the use of multiple medications and/or the consumption of inappropriate medications because new medications escalate their prevalence and JOURNAL OF CLINICAL ONCOLOGY complexity, which consequently increases the risk for adverse drug effects, drug-drug interactions, and nonadherence as a result of increased pill burden and regimen complexity. [4] [5] [6] [7] [8] Increased pill burden increases the risk of drug-drug, drug-food, and drugherbal interactions, and medical oncologists may not know how to manage such issues.
A comprehensive medication review is considered to be an integral part of the geriatric oncology assessment. 9,10 Extermann et al 9 and the National Comprehensive Cancer Network Older Adult Oncology Guidelines 10 both recommend a comprehensive medication assessment, which includes a thorough a review of patients' medications with subsequent discontinuation of any nonessential medications and evaluation for drug interactions, adverse effects, and patient adherence; however, such guidelines do not state which health care professional should be performing the medication assessment. Existing studies that report on the prevalence of PP and PIM use, specifically in ambulatory senior adults with cancer, report the prevalence of PP as 48% to 80% and PIM use as 8% to 41%. These studies are scarce and are limited by antiquated criteria and/or screening tools for defining PP and PIM use, and excessive polypharmacy (EPP) has never been examined. [11] [12] [13] [14] In addition, the methodologies used in previous studies were flawed by the inherent pitfalls in measuring medication use by using patient self-reports and medical records extraction compared with using a pharmacist-led comprehensive medication assessment, which should be recognized as a best practice benchmark. On that basis, we designed this study to examine the prevalence of PP, EPP, and PIM use and factors influencing their use on the basis of a pharmacist-led comprehensive medication assessment in ambulatory senior adults with cancer at our institution.
PATIENTS AND METHODS
This protocol was approved by the institutional review board at our institution before initiation. This was a retrospective study (data were collected from physicians' and clinical pharmacists' electronic progress notes documented in the electronic medical record). All patients who received an initial geriatric oncology assessment at our senior adult oncology ambulatory center between January 2011 and June 2013 and had a diagnosis of cancer (all cancer types and all cancer stages) were included in the study. Our center is an outpatient ambulatory center that provides half-day services (5 hours) twice per week at two sites within the health care system. The core Older Adult Oncology multidisciplinary team consisted of a medical oncologist, geriatrician, patient navigator, clinical pharmacist, social worker, and a registered dietician. As a standard of care at our center, patients were instructed to bring in all medications (prescription, nonprescription, herbals, and supplements) for the pharmacist-patient session. During the session, the pharmacist evaluated each medication with the patient and/or caregiver to confirm medication possession and/or self-administration, indication, and adverse effects; in addition, the pharmacist assessed the patient's ability to read medication label directions and to manage medications in an organized manner. The pharmacist provided medication-related education, addressed medication-related problems with the patient and the interdisciplinary health care team, updated the medication record, and documented a progress note in the electronic medical record. The pharmacist's medication-related recommendations (eg, discontinuation of unnecessary and/or inappropriate medications, recommendation of alternatives) were part of the comprehensive assessment and were forwarded to the primary oncologist and/or medical provider for evaluation and follow-up. PP was defined as concurrent use of five or more and less than 10 medications, and EPP was defined as concurrent use of 10 or more medications, including prescription, nonprescription, herbal, and supplement medications. [15] [16] [17] [18] PIM use was categorized on the basis of three screening tools, including the 2012 Beers criteria, the Screening Tool of Older Person's Prescriptions (STOPP) criteria, and the Healthcare Effectiveness Data and Information Set (HEDIS) criteria for drugs to avoid in the elderly. [19] [20] [21] [22] [23] These three screening tools were used in this study because they represent the most current, evidence-based, clinically validated criteria in the literature. There is no head-to-head trial that recommends the use of one screening tool over another, so each of these tools is considered a viable option for use in clinical practice. The 2012 Beers criteria is the screening tool used in clinical practice in the United States and is supported and endorsed by the American Geriatrics Society. The STOPP criteria is a European screening tool developed on the basis of expert consensus and evidence-based criteria, and it incorporates commonly encountered instances of potentially inappropriate prescribing in senior adults, and it includes drug-drug and drug-disease interactions, drugs that adversely affect seniors at risk of falls, and duplicate drug class prescriptions. HEDIS is a health care quality measure used in the United States that was created by the National Committee on Quality Assurance to examine the quality of prescribing for older patients. The American Geriatrics Society stated that the STOPP criteria should be used in a complementary manner with 2012 Beers criteria to guide clinicians in making decisions about safe medication use in senior adults, largely because there are some notable differences between these screening tools.
Demographic and clinical patient information was collected from medical records and included age, sex, race, cancer type and cancer stage, comorbidities (number and type), and Eastern Cooperative Oncology Group (ECOG) performance status 24 and functional status by using stages of aging described as fit, vulnerable, or frail as determined by the geriatrician. Balducci et al 25 defined "fit" patients as those who lacked serious comorbidity and were functionally independent without evidence of geriatric syndromes. "Vulnerable" patients were dependent in one or more instrumental activities of daily living and had several more significant comorbid conditions. "Frail" patients were dependent in activities of daily living, had evidence of geriatric syndromes, and had significant comorbidities. PP and PIM factors that influenced or were associated with age, sex, PP, comorbidities, ECOG performance status, and functional status were analyzed. Descriptive statistics were calculated by using Fisher's exact test, Pearson's 2 test for categorical variables, Wilcoxon's test for continuous variables, and the Kruskal-Wallis test for assessments between groups.
RESULTS
Data were collected from 248 consecutive patients who received an initial geriatric oncology assessment at our institution between January 2011 and June 2013. The mean age was 80 years, 159 patients (64%) were women, and the mean number of comorbidities was 7.69 (excluding primary cancer). Two hundred sixteen patients (87%) had solid tumors, and 32 patients (13%) had hematologic malignancies. A majority with solid tumors had advanced-stage or metastatic disease. Table 1 displays the distribution of patients' baseline characteristics  and Table 2 identifies patient characteristics by comorbidity type. Of the 248 patients evaluated at our center, 234 (94%) were seen by a clinical pharmacist for a comprehensive medication assessment and were included in the final analysis (the remaining 14 patients were evaluated on days on which pharmacist coverage was not readily available). Evaluation of the 234 patients by a clinical pharmacist showed that they took 2,163 total medications, 1,430 prescription medications, 647 nonprescription medications, and 86 herbal medications. The mean number of medications used by patients was 9.23 (standard deviation [SD], 4.79; range, 1 to 30 medications). The medications were as follows: 6.1 prescription medications (SD, 3.58; range, 0 to 20 prescription medications), 2.76 nonprescription medications (SD, 2.11; range, 0 to 10 nonprescription medications), and 0.38 herbal medications (SD, 0.88; range, 0 to 10 herbal medications;). The prevalence of PP, EPP, and PIM use was 41%, 43%, and 51%, respectively. Table 3 shows that the most common prescription medications were drugs that act on the cardiovascular system at a prevalence of 77%, dyslipidemics at 53%, GI medications at 41%, diuretic medications at 40%, and endocrine-related medications at 37%. Appendix Table A1 (online only) lists comorbidity types associated with PP category. 2012 Beers, STOPP, and HEDIS criteria classified 173 occurrences of PIMs present in 40% (n ϭ 94), 38% (n ϭ 88), and 21% (n ϭ 49) of patients, respectively. BEERs and STOPP criteria were most inclusive, each detecting 118 occurrences, and HEDIS detected 58 occurrences (of 173 occurrences). Mutual overlap between Beers and STOPP criteria occurred in 38% of PIM use (66 of 173 occurrences). The mean number of inappropriate medications used by patients was 0.74 (SD, 0.89; range, 0 to 4 inappropriate medications). The proportion of study participants who were prescribed 0, 1, 2, 3, and 4 PIMs was 49%, 34%, 12%, 4%, and 1%, respectively. The most prevalent PIMs are listed in Table 4 and include benzodiazepines (16%), GI medications (9.4%), nonsteroidal anti-inflammatory drugs (8.5%), antiplatelet medications (8%), and first-generation antihistamines (6%). The most common medications detected by 2012 Beers (but not by STOPP) criteria were short-and intermediate-acting benzodiaz-epines and sedative hypnotics. The most common medications detected by STOPP (but not by 2012 Beers) criteria were antiplatelet medications (specifically, aspirin at doses above 150 mg per day), beta-blockers (noncardioselective beta-blocker with chronic obstructive pulmonary disease), and proton pump inhibitors (for peptic ulcers at the full therapeutic dose for more than 8 weeks). In Table 5 , patient characteristics associated with PP were increased number of comorbidities, increased PIM use, reduced ECOG performance status at baseline, and reduced functional status at baseline. Patient characteristics associated with PIM use (v no PIMs) were PP (P Ͻ .001) and increased number of comorbidities (P ϭ .005), as listed in Table 6 . Specific comorbidities that were associated with PIM use were cardiovascular (P ϭ .014), GI (P ϭ .013), neurologic (P ϭ .020), and psychiatric (P Ͻ .001) conditions, as summarized in Appendix Table A2 (online only). The rate of PIM use differs between PP categories, as illustrated in Appendix Figure A1 (online only). The mean number of PIMs used between no PP, PP, and EPP is 0.19, 0.6, and 1.07, respectively. The PIM use rate between no PP and PP is 6% versus 9% (P Ͻ .001).
DISCUSSION
In this cohort of senior adult oncology patients, a pharmacist-led medication assessment identified a high prevalence of PP, EPP, and PIM use compared with previously reported methodologies. Studies reporting on the prevalence of PP and PIM use, specifically in ambulatory older adults with cancer, are limited. Lichtman et al 11 published an abstract on PIM use in older patients with cancer in the outpatient setting. The investigation identified PIM use in 11% of patients on the Our study shows a mean number of 9.2 medications used by the cohort, 41% prevalence of PP, and 43% prevalence of EPP, which is slightly higher than in previous publications. The reduced prevalence of PP reported by previous publications may be associated with the fact that previous investigations were based on antiquated criteria and/or screening tools for defining PP and PIM use in the elderly, and EPP was not defined or examined in any of these studies. The majority of these investigations assessed medications and medication use on the basis of usual care standards, defined as physician-or prescriberdirected medication assessments documented in medical records and/or medication databases compared with a pharmacist-directed comprehensive medication assessment, which may explain a higher prevalence of PP in our study compared with that in previous publications. Similarities between 2012 Beers and STOPP criteria include nonsteroidal anti-inflammatory drugs, tricyclic antidepressant medications, and long-acting benzodiazepine medications. Differences include items in the STOPP criteria such as the use of noncardioselective beta blockers in chronic obstructive pulmonary disease, the use of aspirin at dosages greater than 150 mg per day, and the use of proton pump inhibitors for treatment durations of greater than 8 weeks, which are not included in 2012 Beers criteria. The American Geriatrics Society highlights the notion that the STOPP criteria be used in a complementary manner with 2012 Beers criteria to guide clinicians in making decisions about safe medication use in senior adults. This recommendation is accurate and is reinforced by the fact that in our study, there was insufficient overlap between the 2012 Beers and STOPP criteria, because both tools combined mutually identified 66 (38%) occurrences of PIM use, further supporting the fact that use of both tools may be seen as complementary.
In this study, patient characteristics associated with PP (v no PP) were increased number of comorbidities (P Ͻ .001), increased PIM use (PϽ.001), reduced ECOG performance status at baseline (Pϭ.005), and reduced functional status at baseline (P Ͻ .001). Prithviraj et al 13 found that patients who were taking five or more medications (compared with Ͻ 5 concurrent medications) were statistically significantly more likely to have poor functional status, have five or more comorbidities, and be prescribed a PIM per 2012 Beers criteria. The authors found an association between medication use and ECOG performance scores, with patients taking multiple medications more likely to have poorer performance status, which was also found in our study. Finally, our study found associations between PIM use (v no PIM use) and PP (P Ͻ .001) and increased number of comorbidities (P ϭ .005), specifically cardiovascular, GI, neurologic, and psychiatric conditions.
To the best of our knowledge, our study is the first of its kind to incorporate a pharmacist-led comprehensive medication assessment using the most current, evidence-based, clinically validated criteria and screening tools to examine the prevalence of PP, EP, and PIM use in this complex population. Studies show that when pharmacists are involved in care transitions and take measures to decrease the prevalence of multiple medication use and medication-related problems, hospital readmission rates and preventable adverse drug events are reduced; however, these studies are mostly limited to the inpatient setting in the area of medication reconciliation and discharge programs. 3, [27] [28] [29] [30] [31] [32] [33] Although these inpatient programs provide a robust framework, identifiable gaps exist because the literature does not focus on the ambulatory care setting or the oncology population. Integrating clinical pharmacy services in this multidisciplinary team may have the potential to optimize patient medication use and health outcomes by providing comprehensive medication assessment and planning (for both oncology and medicine issues), all before initiating cancer and/or supportive care treatment.
This study has some shortcomings that limit its clinical applicability to the larger population. This was a single-institution study with a small sample size compared with some previous studies. Medication use was assessed at a single (initial) visit in which most patients were not receiving any anticancer treatments or cancer-related therapies. Medication use in this population changes continuously, especially for the patients who will begin anticancer and/or supportive care-related therapies, so follow-up data on acceptance of pharmacist interventions would strengthen study findings. Finally, patient outcomes associated with excessive and inappropriate medication use-increased use of health care resources (eg, hospitalizations) and adverse events that compromised cancer management plans-were not captured. A pharmacist-led comprehensive Older Adult Oncology medication assessment demonstrated a high prevalence of PP, EPP, and PIM use versus previously reported methodologies. The prevalence of PIMs varied depending on the screening tool applied, yet the 2012 Beers criteria detected the highest prevalence of PIM use in this population. Because of the minimal overlap between 2012 Beers and STOPP criteria, a modified PIM tool that integrates 2012 Beers and STOPP criteria and considers cancer diagnosis, prognosis, and cancer-related therapy is needed to identify and minimize PIM use. Additional follow-up studies are needed to longitudinally evaluate medication use to identify associations with increased risk of adverse events that compromise cancer management plans and worsen patient outcomes in this complex and vulnerable population.
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